Table 3

Papers excluded from systematic review

1Gedge J, Orme S, Hampton KK, et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty in elderly patients. Age Ageing 200;29:31–4.
2Johnson MJ. Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Pall Med 1997;11:306–12.
3Roberts GW, Druskeit T, Jorgensen LE, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty’s protocol. Aust N Z J Med 1999;29:731–6.
4Motykie GD, Mokhtee D, Zebala LP, et al. The use of a Bayesian forecasting model in the management of warfarin therapy after total hip arthroplasty. J Arthroplasty 1999;14:988–93.
5Vadher B, Patterson DL, Learning M. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. Br J Clin Pharmacol 1999;48:63–70.
6Hobbs FD, Fitzmaurice DA, Murray ET, et al. Is the international normalised ratio (INR) reliable? A trial of comparative measurements in hospital laboratory and primary care settings. J Clin Pathol 1999;52:494–7.
7Caprini JA, Arcelus JI, Motykie G, et al. The influence of oral anticoagulation therapy on deep vein thrombosis rates for four weeks after total hip replacement. J Vasc Surg 1999;30:813–20.
8Caprini JA, Arcelus JI, Reyna JJ, et al. Deep vein thrombosis outcome and the level of oral anticoagulation therapy. J Vasc Surg 1999;30:805–11.
9Sunderji R, Campbell L, Shalansky K, et al. Outpatient self-management of warfarin therapy: a pilot study. Pharmacotherapy 1999;19:787–93.
10Morsdorf S, Erdlenbruch W, Taborski U, et al. Training of patients for self-management of oral anticoagulant therapy: standards, patient suitability and clinical aspects. Thromb Haemost 1999;25:109–15.
11Schenk JF, Morsdorf S, Pindur G, et al. Analysis and occurrence of adverse events with oral anticoagulant therapy. Thromb Haemost 1999;25:65–71.
12Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999;159:46–8.
13Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. J Cardiol 1999;84:905–8.
14Cheung YF, Leung MP. Low dose oral anticoagulation therapy in Chinese children with congenital heart disease. J Paediatr Child Health 1998;34:563–7.
15Gerstein FH, Evans MF. When the INR comes back too high. Can Fam Physician 1998;44:1841–2.
16Oates A, Jackson PR, Austin CA, et al. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998;46:157–61.
17The Newcastle Anticoagulation Study Group. Effectiveness of anticoagulation among patients discharged from hospital on warfarin. Med J Aust 1998;169:243–6.
18Tait RC, Sefcick A. A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. Br J Haematol 1998;101:450–4.
19Fitzmaurice DA, Hobbs FDR, Murray ET. Primary care anticoagulant clinic management using computerized decision support and near patient international normalized ratio (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 1998;15:144–6.
20Seamark DA, Backhouse S, Barber P, et al. Validation of current practice and a near patient testing method for oral anticoagulant control in general practice. J R S Med 1997;90:657–60.
21Palareti G, Manotti CD, Angelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception cohort, prospective collaborative ISCOAT study. Thromb Haemost 1997;78:1438–43.
22Dedden P, Chang B, Nagel D. Pharmacy managed program for treatment of deep vein thrombosis with enoxaparin. American Journal of Clinical Pharmacy 1997;54:1968–72.
23Hasenkam JM, Kimose HH, Knudsen L, et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997;11:935–42.
24Carroll WE, Jackson RD. Warfarin monitoring independent of the international normalized ratio (INR): a pilot study. Res Commun Mol Pathol Pharmacol 1997;95:169–78.
25Harrison L, Johnson M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133–6.